Engflag

Tofacitinib

Quick links to important sections

Tofacitinib

Tofacitinib_PL

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tofacitinib

Quick Facts

Property Description
Active Ingredient Tofacitinib (INN)
Form Oral tablet (Immediate or Extended Release)
Pharmacological Class Janus kinase (JAK) Inhibitor
Origin Synthetic small molecule (chemically manufactured)
Common Use Treating chronic, moderate-to-severe autoimmune and inflammatory diseases

What Type of Medicine is Tofacitinib?

Tofacitinib is an oral medication categorized as a Janus kinase (JAK) inhibitor, placing it in the modern class of targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (tsDMARDs). The active ingredient, Tofacitinib, is a synthetic small molecule that is chemically manufactured to interfere with specific signaling pathways inside cells. This composition allows it to be taken by mouth as a tablet, distinguishing it from large-protein biologics that often require injection or infusion.

Tofacitinib provides a novel approach to treat inflammatory autoimmune diseases by selectively blocking certain signaling pathways. This medicine works from the inside of cells to interrupt the signaling pathways that drive inflammation.

What is the Primary Purpose and Unique Feature of Tofacitinib?

The primary purpose of Tofacitinib is to modulate the immune system to help manage the activity and progression of chronic, moderate-to-severe autoimmune and inflammatory diseases. It serves as a targeted therapy for adult patients who have had an inadequate response to, or cannot tolerate, more traditional therapies, such as older nonbiologic DMARDs.

One key distinguishing feature of Tofacitinib is its oral tablet formulation—available in both Immediate and Extended Release forms—which offers a unique convenience factor compared to many other advanced therapies. Tofacitinib works by decreasing the activity of the immune system to manage symptoms and prevent the loss of function caused by the underlying conditions. This means the drug helps control persistent inflammation, leading to less pain and stiffness over time for patients.

Regulatory References

  1. NIH StatPearls
  2. National Library of Medicine

What side effects are possible with Tofacitinib?

The safety profile of Tofacitinib is derived from regulatory classifications that group adverse reactions by frequency and physiological system.

Adverse Reactions and Official Classifications

Adverse reactions are classified according to regulatory frequency: Very Common (ge 1/10) events include upper respiratory tract infection and nasopharyngitis. Common (ge 1/100 to < 1/10) events include headache, diarrhea, nausea, neutropenia, and Herpes Zoster (shingles).

Reactions are grouped by system, including the Infections and infestations and Blood and lymphatic system disorders (e.g., anemia, lymphopenia, neutropenia). Changes in laboratory parameters, such as elevated cholesterol levels, are commonly documented.

Serious Safety Risks and Constraints

The label highlights serious adverse reactions, including serious and opportunistic infections (e.g., tuberculosis, fungal infections), malignancies (cancers, including lymphoma and lung cancer), Major Adverse Cardiovascular Events (MACE) (e.g., heart attack, stroke), and Thrombosis (Venous Thromboembolism, including DVT and PE).

Regulatory documents specify that the risk of these serious events is higher in specific populations, notably older adults (aged 50 and older) with at least one cardiovascular risk factor, and current or past smokers. Use is not recommended in combination with biologic DMARDs or other potent immunosuppressants. Patients must be screened for latent tuberculosis prior to initiation, and ongoing laboratory monitoring of blood counts and liver enzymes is mandated.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Tofacitinib states that there is no specific antidote for an overdose, and no specific acute single-dose symptoms are listed. Management is focused strictly on supportive measures and addressing the known, dose-limiting toxicities of the medicine.

Official Regulatory Requirements

Feature Official Regulatory Statement
Documented Manifestations Excessive exposure is expected to exacerbate dose-related toxicities, including severe lymphopenia, neutropenia, and anemia (low blood cell counts).
Urgent Medical Actions Required Patients must seek emergency medical attention right away if they experience symptoms of severe adverse events, such as sudden shortness of breath or chest pain (signs of Thrombosis or MACE).
Supportive Management The patient should be monitored for adverse reactions and receive appropriate symptomatic treatment. The medicine must be discontinued immediately if thrombosis symptoms occur.
Antidote Availability The official labeling explicitly states that no specific antidote is available for Tofacitinib overdose.

Connection to the Overall Overdose Profile

The regulatory profile defines the overdose situation by the absence of an antidote and the imperative for symptomatic support. It emphasizes that the dose-exaggerated risks, particularly Thrombosis (DVT/PE), are the most critical, life-threatening outcomes that necessitate immediate contact with emergency services, as explicitly stated in government labeling.

Therapeutic Uses of Tofacitinib

What Tofacitinib Treats: Main Uses and Benefits

Tofacitinib is a therapy that supports the management of symptoms associated with chronic, active autoimmune and inflammatory conditions. It is generally used for adult patients whose disease has not responded adequately to, or who cannot tolerate, conventional synthetic treatments.

This medication is used to address conditions presenting with systemic or localized discomfort and inflammatory processes. These conditions generally include moderately to severely active Rheumatoid Arthritis (RA), Active Psoriatic Arthritis (PsA), Active Ankylosing Spondylitis (AS), and Ulcerative Colitis (UC), as well as Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA) in pediatric patients aged 2 and older.

The medication is commonly used to help ease the overall symptom burden:

“The therapy is applied in addressing the persistent pain, swelling, and stiffness that interfere with daily functioning.”

Quick Fact: Relief for Inflammatory Symptoms

Symptom Focus Therapeutic Goal
Active Joint Symptoms Assists with maintaining physical function and mobility.
Systemic Activity Supports management of persistent, chronic disease progression.
Bowel Inflammation Contributes to easing the overall symptom load during active UC.

By addressing symptom clusters related to heightened physiological activity, Tofacitinib offers symptomatic relief for difficult episodes and helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Tofacitinib is an oral medication with specific eligibility criteria defined by regulatory authorities for patient selection and exclusion.

Populations for Whom Use is Restricted or Prohibited

Classification Population/Condition Restriction Basis
Contraindicated Active tuberculosis or other serious infections Prohibited by official labeling [Source 2.2, 3.5]
Contraindicated Severe hepatic impairment (Child-Pugh C) Prohibited by official labeling [Source 1.5, 3.5]
Contraindicated Pregnancy and Breastfeeding Prohibited by official labeling [Source 2.2]
Restricted Use Elderly (ge 65 years) or patients with cardiovascular risk factors Use conditional on the lack of suitable alternative treatments [Source 2.1, 2.4]

Age-Related and Health-Condition Eligibility

Approved Age Groups: Tofacitinib is officially approved for adult patients across all labeled conditions, and for pediatric patients aged 2 years and older with Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA) and Juvenile Psoriatic Arthritis [Source 1.1, 1.4]. Use in children under 2 years of age has not been established [Source 4.1].

Health Restrictions: Regulators advise against initiation if certain blood count thresholds are unmet, such as an Absolute Neutrophil Count (ANC) less than 1000 cells/mm^3 [Source 1.5]. The standard use is restricted for patients with moderate or severe renal impairment or moderate hepatic impairment [Source 2.4]. Furthermore, use with biologic DMARDs or potent immunosuppressants is not recommended [Source 1.2].

What should I know about interactions with other medicines?

Tofacitinib Interactions with other medicines and products

The official interaction profile for Tofacitinib is structured around metabolic and pharmacodynamic constraints as defined in regulatory documents. The pharmacokinetic profile is centered on the CYP3A4 enzyme, which serves as the major metabolic pathway, alongside the CYP2C19 pathway.

Co-administration with potent CYP3A4 inhibitors (such as ketoconazole) or with combined moderate CYP3A4 and potent CYP2C19 inhibitors (such as fluconazole) significantly increases Tofacitinib plasma concentration. Due to this change in exposure, regulatory documents mandate a dose reduction when combining with these specific agents. Conversely, co-administration with potent CYP3A4 inducers (such as rifampicin) is not recommended because it decreases Tofacitinib exposure, potentially leading to a loss of clinical response.

Pharmacodynamic constraints result in formal restrictions on combination therapy due to the risk of additive immunosuppression. The use of Tofacitinib in combination with biologic DMARDs or other potent immunosuppressants (such as azathioprine or ciclosporin) is officially not recommended. Additionally, co-administration with live vaccines must be avoided. Official labeling confirms that Tofacitinib can be administered with or without food, indicating a lack of a clinically significant drug-food interaction. Interaction risks involving CYP inhibitors are heightened in patients with moderate or severe renal impairment or moderate hepatic impairment.

Mechanism of Action

Tofacitinib is a targeted synthetic small molecule that acts inside immune cells to modulate the JAK-STAT signaling pathway. As a competitive inhibitor, the drug binds reversibly to the ATP-binding site of Janus Kinase (JAK) enzymes, preferentially targeting JAK1 and JAK3, while also influencing JAK2 and TYK2. This molecular interaction prevents JAK activation, which interrupts the signal chain for numerous inflammatory cytokines (e.g., IL-2, IL-6, IL-7).

By blocking JAK activity, Tofacitinib prevents the phosphorylation and nuclear entry of STAT proteins, which reduces the transcription of genes responsible for producing inflammatory mediators, such as chemokines and Matrix Metalloproteinases. This action results in a reduction of immune cell proliferation and decreased expression of signaling proteins necessary for recruiting cells to tissues. The mechanism influences the processes that lead to excessive immune activation, resulting in the modulation of systemic inflammatory signals, evidenced by an alteration in inflammatory biomarkers ( CRP) following treatment. Its partial effect on JAK2 means the mechanism also influences systems like hematopoiesis**, as JAK2 signaling is integral to those pathways.

Dosage and Administration Information

How to Use Tofacitinib

The use of tofacitinib follows specific instructions for administration. This medicine is administered orally (taken by mouth).

Dosing and Administration Rules

Instruction Domain Specific Requirement
Route & Timing Taken orally and may be administered with or without food.
Standard Dosing The dose varies by formulation and condition. Commonly, immediate-release (IR) tablets are taken 5 mg twice daily (BID), or extended-release (XR) tablets are taken 11 mg once daily (QD).
Preparation Extended-release (XR) tablets must be swallowed whole and must not be crushed, split, or chewed.
Pediatric Use Specific weight-based dosing schedules are established for children and adolescents with certain conditions, such as Polyarticular Juvenile Idiopathic Arthritis (PJIA) starting at age 2 years.

Procedural Guidelines

Adherence to established procedural steps is part of the therapy:

  • Required Monitoring: Tofacitinib initiation and continuation depend on meeting specific blood cell thresholds. Therapy is not started or is interrupted if absolute lymphocyte count (ALC) is below 500 cells/ mm^3, absolute neutrophil count (ANC) is below 1,000 cells/ mm^3, or hemoglobin is below 8 g/ dL.
  • Missed Dose: If a dose is missed, it is not taken late. The next scheduled dose is taken at the regular time.
  • Dose Modification: Dosing is adjusted (typically reduced) for patients with moderate to severe kidney impairment or moderate liver impairment, as well as when used concurrently with certain medications that affect drug clearance.

Recent Clinical Evidence

Tofacitinib: Recent Clinical Evidence

Efficacy in Rheumatoid Arthritis and Psoriatic Arthritis

Studies have investigated Tofacitinib's association with changes in disease activity and physical function in adults with moderately to severely active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

  • RA Trials: Research examined whether treatment with Tofacitinib, when used alone or in combination with nonbiologic disease-modifying antirheumatic drugs (DMARDs), correlated with changes in clinical endpoints such as the American College of Rheumatology (ACR) response criteria.
  • PsA Trials: Evidence was evaluated regarding its potential association with changes in joint inflammation, skin lesions, and physical function, often using the Psoriatic Arthritis Response Criteria (PsARC) and other standardized measures.

Pharmacologic Action and Administration Context

Research suggests Tofacitinib may act by inhibiting Janus kinases (JAKs), which are enzymes that play a role in the signaling pathways of several cytokines involved in inflammation.

  • Absorption: Following oral administration, the drug is rapidly absorbed. Food intake was examined in studies and found not to significantly affect the overall exposure of the drug in the body.
  • Metabolism: Studies indicate that Tofacitinib is primarily metabolized in the liver, with a smaller portion eliminated unchanged by the kidneys. This process involves multiple metabolic enzymes.

Safety Monitoring and Long-term Data

Long-term data from open-label extension studies and post-marketing surveillance programs have evaluated the sustained observed effects of Tofacitinib, particularly focusing on safety endpoints over extended treatment periods. Research continues to investigate potential associations between Tofacitinib use and certain risks, including the incidence of major adverse cardiovascular events (MACE) and malignancies.

How should Tofacitinib be stored and disposed of?

Storage and Disposal Requirements

All forms of tofacitinib must be stored according to official regulatory specifications to maintain product integrity and ensure patient safety. The medication must be kept out of the reach of children.

Domain Official Regulatory Requirement
Temperature & Protection Store at controlled room temperature (20 C to 25 C), protected from light, and in the original container [Source: FDA, NIH].
Oral Solution Handling The oral solution must not be frozen. It must be discarded 60 days after the bottle is first opened [Source: NIH].
Disposal Instructions Unused or expired tablets, if not handled through a local take-back program, must be mixed with an undesirable substance (e.g., dirt, coffee grounds) and placed in a sealed container before disposal in household trash [Source: FDA]. The medication is not on the FDA's flush list [Source: FDA].

These rules define the required ambient environment for storage and provide mandatory procedures for handling the oral solution's in-use stability and the proper disposal of unused tablets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tofacitinib found in:

A-Z Index: